Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic...
Last updated: 2026-04-10 18:43:47 ET
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic...
Apparel retailers could see an up to $13 billion annual boost in spending because of GLP-1 drugs, according to an estimate by equity research firm Ber...
Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
A 59-year-old man lost 25 pounds on Foundayo, the new GLP-1 weight-loss pill
Also in Weekend Reads: The global energy market’s long road back after the Iran conflict ends, differences between new GLP-1 pills, and a simple 50/...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE